Pfizer's Phase 3 Study Shows Sasanlimab with BCG Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer

Jan 10, 2025, 11:52 AM

Pfizer has announced positive topline results from its Phase 3 study indicating that Sasanlimab, when combined with Bacillus Calmette-Guérin (BCG), improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint as assessed by investigators. Pfizer also reported that the safety profile of Sasanlimab was consistent with previous findings, suggesting a favorable outcome for this treatment approach in a challenging patient population.